ASX CODE: CYP
Cynata Therapeutics receives notice of allowance ahead of patent for stem cell platform
A patent covering a stem cell technology platform developed by Cynata Therapeutics (ASX: CYP) appears on the horizon, following the receipt of a Notice...
Cynata Therapeutics finalises Cymerus patent to treat adverse reactions to cancer immunotherapy
Cynata Therapeutics (ASX: CYP) has wrapped up an IP Australia patent application for therapeutic use of its Cymerus stem cell technology in treating adverse reactions...
Cynata receives key FDA approval to progress GvHD drug candidate
For the second time in as many days, the US Food and Drug Administration (FDA) has granted important permission to an ASX-listed company in...
Cynata unveils promising results in treating graft versus host disease with stem cells
Cynata Therapeutics (ASX: CYP) has unveiled “excellent” data from its “world first” clinical trial using its stem cell product CYP-001 in treating steroid resistant...
Cynata finds synergy with US-based biotech developer
Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has signed a Memorandum of Understanding (MoU) with Celularity Inc., a US-based biotech...
Cynata Therapeutics advance to second cohort in stem cell trial
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has received an encouraging early response from the clinical trials of its stem cell...
Cynata Therapeutics enrols first cohort for world first clinical trial
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has enrolled its first cohort for its “world first” clinical trial of its stem...
